DRD4
Dopamine receptor D4
As of the edition of 20 October 2026, DRD4 (dopamine receptor D4, UniProt P21917) has 25 drugs tested at it and 31 companies on the list, 4 on route A and 9 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P21917
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 2
- Disease areas
- Mental health; Nervous system; Nutrition and metabolism; Cancer; Chemically induced; Hormones; Blood and lymph; Heart and blood vessels
- Registered trials of its drugs
- 715
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 18 |
| Active | 1 |
| Stopped | 3 |
| Withdrawn from market | 2 |
| Status not established | 1 |
| Total | 25 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Olanzapine | Marketed | Phase 4 | none listed |
| Pramipexole | Marketed | Phase 4 | none listed |
| Rotigotine | Marketed | Phase 4 | none listed |
| Haloperidol | Marketed | Phase 4 | none listed |
| Ropinirole | Marketed | Phase 4 | none listed |
| Apomorphine | Marketed | Phase 4 | none listed |
| Bromocriptine | Marketed | Phase 4 | none listed |
| Loxapine | Marketed | Phase 4 | none listed |
| Dexpramipexole | Stopped | Phase 3 | none listed |
| Droperidol | Marketed | Phase 4 | none listed |
| Chlorpromazine | Marketed | Phase 4 | none listed |
| Pergolide | Withdrawn from market | Phase 4 | none listed |
12 of 25 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 4 |
| Route B | 9 |
| Engaged | 5 |
| Undetermined | 13 |
| Total on the list | 31 |
The other 28 companies at DRD4
In the product31 companies in all; 28 are not named here, and no score is.
See the 31 companies at DRD4, ranked, with the facts behind eachRequest access. Nothing is shown until you do.